OBJECTIVES: To evaluate the short-term symptomatic efficacy of rofecoxib and diclofenac versus placebo in acute episodes of shoulder pain. DESIGN: Randomized controlled trial of 7 days. SETTING: Rheumatologists and/or general practitioners totaling 47. PARTICIPANTS: Acute shoulder pain. INTERVENTIONS: Rofecoxib 50 mg once daily, diclofenac 50 mg three times daily, and placebo. OUTCOME MEASURES: Pain, functional impairment, patient's global assessment of his/her disease activity, and local steroid injection requirement for persistent pain. The primary variable was the Kaplan-Meier estimates of the percentage of patients at day 7 fulfilling the definition of success (improvement in pain intensity and a low pain level sustained to the end of t...
SummaryObjectiveTo compare the safety and efficacy of acetaminophen extended-release (APAP ER) with ...
BACKGROUND: shoulder pain is a common reason for consultation in primary care and leads in 74 % of c...
Background: Rofecoxib is a cyclo-oxygenase 2 selective inhibitor. This systematic review of rofecoxi...
OBJECTIVES: To evaluate the short-term symptomatic efficacy of rofecoxib and diclofenac versus place...
To evaluate the short-term symptomatic efficacy of rofecoxib and diclofenac versus placebo in acute ...
Objective: To evaluate the efficacy and safety of oxaprozin in comparison with diclofenac in patient...
Aim of study: To examine the prevalence of low intensity symptom severity states in patients taking ...
Objective : To evaluate the efficacy and tolerability of rofecoxib 25 mg and 50 mg once daily versus...
Background: Rofecoxib is a potent cyclo-oxygenase-2 inhibitor with a long duration of action. Its ro...
Objective: Topical diclofenac is widely used in the treatment of pain and inflammation. This compreh...
Objective. To compare the effectiveness of corticosteroid injections with physiotherapy for the trea...
Objective: To compare the treatment efficacy between corticosteroid injection and nonsteroidal anti-...
Joint pain is the main complaint in patients affected by osteoarthritis (OA), and NSAIDs are commonl...
Background: We aimed to investigate whether the addition of non-steroidal anti-inflammatory drugs or...
Diclofenac Potassium sachets (DPS) is a new faster-absorption and rapid onset of pain relief drug do...
SummaryObjectiveTo compare the safety and efficacy of acetaminophen extended-release (APAP ER) with ...
BACKGROUND: shoulder pain is a common reason for consultation in primary care and leads in 74 % of c...
Background: Rofecoxib is a cyclo-oxygenase 2 selective inhibitor. This systematic review of rofecoxi...
OBJECTIVES: To evaluate the short-term symptomatic efficacy of rofecoxib and diclofenac versus place...
To evaluate the short-term symptomatic efficacy of rofecoxib and diclofenac versus placebo in acute ...
Objective: To evaluate the efficacy and safety of oxaprozin in comparison with diclofenac in patient...
Aim of study: To examine the prevalence of low intensity symptom severity states in patients taking ...
Objective : To evaluate the efficacy and tolerability of rofecoxib 25 mg and 50 mg once daily versus...
Background: Rofecoxib is a potent cyclo-oxygenase-2 inhibitor with a long duration of action. Its ro...
Objective: Topical diclofenac is widely used in the treatment of pain and inflammation. This compreh...
Objective. To compare the effectiveness of corticosteroid injections with physiotherapy for the trea...
Objective: To compare the treatment efficacy between corticosteroid injection and nonsteroidal anti-...
Joint pain is the main complaint in patients affected by osteoarthritis (OA), and NSAIDs are commonl...
Background: We aimed to investigate whether the addition of non-steroidal anti-inflammatory drugs or...
Diclofenac Potassium sachets (DPS) is a new faster-absorption and rapid onset of pain relief drug do...
SummaryObjectiveTo compare the safety and efficacy of acetaminophen extended-release (APAP ER) with ...
BACKGROUND: shoulder pain is a common reason for consultation in primary care and leads in 74 % of c...
Background: Rofecoxib is a cyclo-oxygenase 2 selective inhibitor. This systematic review of rofecoxi...